MoonLake Immunotherapeutics
Update in progressMLTX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific Nanobody that inhibits IL-17A and IL-17F, for dermatology and rheumatology inflammatory conditions, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. Founded in 2021, it is headquartered in Zug, Switzerland.
Company score
- Sentiment
- 0.15
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- -0.21
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.08
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationSwitzerland
- CEODr. Jorge Santos da Silva Ph.D.
- Founded2021
- Employees130
- Websitewww.moonlaketx.com
Identifiers
- ISINKY61559X1045
- FIGIBBG00XQZQTS9
- CIK0001821586